Literature DB >> 15047700

Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis.

Ilan Ifergan1, Assaf Shafran, Gerrit Jansen, Jan Hendrik Hooijberg, George L Scheffer, Yehuda G Assaraf.   

Abstract

Breast cancer resistance protein (BCRP/ABCG2) is currently the only ABC transporter that exports mono- and polyglutamates of folates and methotrexate (MTX). Here we explored the relationship between cellular folate status and BCRP expression. Toward this end, MCF-7 breast cancer cells, with low BCRP and moderate multidrug resistance protein 1 (MRP1/ABCC1) levels, and their mitoxantrone (MR)-resistant MCF-7/MR subline, with BCRP overexpression and low MRP1 levels, were gradually deprived of folic acid from 2.3 microm to 3 nm resulting in the sublines MCF-7/LF and MCF-7/MR-LF. These cell lines expressed only residual BCRP mRNA and protein levels and retained a poor MRP2 (ABCC2) through MRP5 (ABCC5) expression. Furthermore, MCF-7/MR-LF cells also displayed 5-fold decreased MRP1 levels relative to MCF-7/MR cells. In contrast, BCRP overexpression was largely retained in MCF-7/MR cells grown in MR-free medium containing 2.3 microm folic acid. Loss of BCRP expression in MCF-7/LF and MCF-7/MR-LF cells resulted in the following: (a) a prominent decrease in the efflux of Hoechst 33342, a BCRP substrate; (b) an approximately 2-fold increase in MR accumulation as revealed by flow cytometry; this was accompanied by a 2.5- and approximately 84-fold increased MR sensitivity in these cell lines, respectively. Consistently, Ko143, a specific BCRP inhibitor, rendered MCF-7 and MCF-7/MR cells 2.1- and approximately 16.4-fold more sensitive to MR, respectively. Loss of BCRP expression also resulted in the following: (c) an identical MTX sensitivity in these cell lines thereby losing the approximately 28-fold MTX resistance of the MCF-7/MR cells; (d) an approximately 2-fold increase in the 4- and 24-h accumulation of [(3)H]folic acid. Furthermore, MCF-7/MR-LF cells displayed a significant increase in folylpoly-gamma-glutamate synthetase activity. Hence, consistent with the mono- and polyglutamate folate exporter function of BCRP, down-regulation of BCRP and increased folylpoly-gamma-glutamate synthetase activity appear to be crucial components of cellular adaptation to folate deficiency conditions. This is the first evidence for the possible role of BCRP in the maintenance of cellular folate homeostasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047700     DOI: 10.1074/jbc.M401725200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Polyadenylation and degradation of human mitochondrial RNA: the prokaryotic past leaves its mark.

Authors:  Shimyn Slomovic; David Laufer; Dan Geiger; Gadi Schuster
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

Review 2.  Mechanisms of membrane transport of folates into cells and across epithelia.

Authors:  Rongbao Zhao; Ndeye Diop-Bove; Michele Visentin; I David Goldman
Journal:  Annu Rev Nutr       Date:  2011-08-21       Impact factor: 11.848

3.  A dominant negative heterozygous G87R mutation in the zinc transporter, ZnT-2 (SLC30A2), results in transient neonatal zinc deficiency.

Authors:  Inbal Lasry; Young Ah Seo; Hadas Ityel; Nechama Shalva; Ben Pode-Shakked; Fabian Glaser; Bluma Berman; Igor Berezovsky; Alexander Goncearenco; Aharon Klar; Jacob Levy; Yair Anikster; Shannon L Kelleher; Yehuda G Assaraf
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

Review 4.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 5.  Identifying genomic and developmental causes of adverse drug reactions in children.

Authors:  Mara L Becker; J Steven Leeder
Journal:  Pharmacogenomics       Date:  2010-11       Impact factor: 2.533

6.  Role of the breast cancer resistance protein (ABCG2) in drug transport.

Authors:  Qingcheng Mao; Jashvant D Unadkat
Journal:  AAPS J       Date:  2005-05-11       Impact factor: 4.009

7.  Intestinal expression of mouse Abcg2/breast cancer resistance protein (BCRP) gene is under control of circadian clock-activating transcription factor-4 pathway.

Authors:  Ahmed M Hamdan; Satoru Koyanagi; Erika Wada; Naoki Kusunose; Yuichi Murakami; Naoya Matsunaga; Shigehiro Ohdo
Journal:  J Biol Chem       Date:  2012-03-06       Impact factor: 5.157

8.  Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.

Authors:  Antonius E van Herwaarden; Els Wagenaar; Gracia Merino; Johan W Jonker; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Journal:  Mol Cell Biol       Date:  2006-12-04       Impact factor: 4.272

9.  Developmental pharmacogenetics in pediatric rheumatology: utilizing a new paradigm to effectively treat patients with juvenile idiopathic arthritis with methotrexate.

Authors:  Mara L Becker; J Steven Leeder
Journal:  Hum Genomics Proteomics       Date:  2010-06-22

10.  Functional regulation of P-glycoprotein at the blood-brain barrier in proton-coupled folate transporter (PCFT) mutant mice.

Authors:  Xueqian Wang; Robert M Cabrera; Yue Li; David S Miller; Richard H Finnell
Journal:  FASEB J       Date:  2012-12-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.